Miroslav Samaržija

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

Roela Sadushi‐Kolici, Pavel Jansa, Grzegorz Kopeć et al. · The Lancet Respiratory Medicine · 2018 · 184 citations · Full text

Thrombosis, Pulmonary Embolism, Hypertension +9

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Suresh S. Ramalingam, Glenwood Goss, Rafael Rosell et al. · Annals of Oncology · 2015 · 106 citations · Full text

Oncology, Heat Shock, Medicine +7

Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer—chemotherapy toxicity and prognostic value

Dražena Srdić, Sanja Pleština, Ana Sverko-Peternac et al. · Supportive Care in Cancer · 2016 · 105 citations

Biochemical Markers, Cancer Cachexia, Medicine +8

Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia

Miroslav Samaržija, Ivan Sabol, Marko Jakopović et al. · The International Journal of Tuberculosis and Lung Disease · 2013 · 69 citations · Full text

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma

Bahil Ghanim, Mir Ali Reza Hoda, Thomas Klikovits et al. · British Journal of Cancer · 2014 · 62 citations · Full text